Janssen Pharmaceuticals Inc. and its development partner Bayer HealthCare announced results from PMSS and XANTUS, real-world safety studies of rivaroxaban (Xarelto) in people with non-valvular atrial fibrillation (NVAF). The results found the rates and patterns of major bleeding in routine clinical practice were low (2.89 and 2.1 per 100 person-years, respectively) and generally consistent with those observed in Phase 3 clinical research.

ABSORB STEMI TROFI II trial, ESC 2015, bioresorbable vascular scaffold, BVS, STEMI patients

A drug-eluting coronary stent made of absorbable material performed similarly to gold-standard metal among patients with an ST-segment elevation myocardial infarction (STEMI), according to results of the ABSORB STEMI TROFI II trial.

Gene transfer therapy to correct an enzyme abnormality involved in myocardial contraction and relaxation did not improve outcomes in heart failure patients with reduced ejection fraction, results of the CUPID 2 study show.

CMS, Medicare Advantage, Value-Based Insurance Design model, VBID, chronic conditions

The Centers for Medicare & Medicaid Services (CMS) announced the creation of the Medicare Advantage Value-Based Insurance Design Model, designed to improve care and reduce costs in Medicare Advantage plans.

Sorin Group announced the start of patient enrollment in its TRIUMPH-CRT clinical trial in Europe.

Most patients with a cardiac resynchronization therapy (CRT) pacemaker would not benefit from the addition of a defibrillator, according to results from the CeRtiTuDe cohort study presented at the European Society of Cardiology (ESC) Congress.

FFR-CT, HeartFlow, PLATFORM trial, ESC 2015, ICA, fractional flow reserve, computed tomography

Results of the PLATFORM trial indicate fractional flow reserve computed tomography (FFR-CT) can obviate the need for invasive tests in up to 61 percent of patients with chest pain and suspected coronary artery disease. The results were presented at the European Society of Cardiology (ESC) Congress 2015.
Alere Triage Troponin I Test
Abbott i-STAT

Hospital-based healthcare providers today are under greater pressure than ever to administer cost- and time-efficient cardiac care that directly enhances patient outcomes. A critical strategy for achieving these goals is the utilization of rapid point-of-care (POC) diagnostics.

An investigational material known as Bioabsorbable Cardiac Matrix (BCM), designed to prevent cardiac remodeling in heart attack patients, had no significant effect compared to a saline placebo, according to a new study.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now